吴一龙教授：CTONG 2003研究荣登 JTO，卡瑞利珠单抗联合放化疗方案助力晚期NSCLC患者颅内及全身PFS双获益！
2025-04-10 MedSci原创 MedSci原创 发表于上海
梅斯医学特邀吴一龙教授就CTONG 2003研究的开展背景、关键数据进行深入解读，并分享免疫治疗在晚期NSCLC领域的应用价值。
参考文献：
1. Lamba Nayan, Wen Patrick Y, Aizer Ayal A, Epidemiology of brain metastases and leptomeningeal disease.[J] .Neuro Oncol, 2021, 23: 1447-1456.
2. 中国医师协会肿瘤医师分会,中国医疗保健国际交流促进会肿瘤内科分会.肺癌脑转移中国治疗指南(2021年版)[J].中华肿瘤杂志 2021年43卷3期, 269-281页, MEDLINE ISTIC PKU CSCD CA BP, 2021.
3. Li Yang-Si, Yu Qitao, Bu Qing, et al. First-Line Camrelizumab Versus Placebo Plus Chemotherapy With or Without Radiotherapy for Brain Metastases in NSCLC: The CTONG 2003 Randomized Placebo-Controlled Trial.[J] .J Thorac Oncol, 2025 Feb 8:S1556-0864(25)00063-2.
4. 郑荣寿, 陈茹, 韩冰峰, 等. 2022年中国恶性肿瘤流行情况分析 [J] . 中华肿瘤杂志, 2024, 46(3) : 221-231.
5. Nadal Ernest, Rodríguez-Abreu Delvys, Simó Marta, et al. Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05).[J] .J Clin Oncol, 2023, 41: 4478-4485.
6. Hou Xue, Zhou Chengzhi, Wu Guowu, et al. Efficacy, Safety, and Health-Related Quality of Life With Camrelizumab Plus Pemetrexed and Carboplatin as First-Line Treatment for Advanced Nonsquamous NSCLC With Brain Metastases (CAP-BRAIN): A Multicenter, Open-Label, Single-Arm, Phase 2 Study.[J] .J Thorac Oncol, 2023, 18: 769-779.
7. Xu Y, Chen K, Xu Y, et al. Brain radiotherapy combined with camrelizumab and platinum-doublet chemotherapy for previously untreated advanced non-small-cell lung cancer with brain metastases (C-Brain): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2025 Jan;26(1):74-84.
8. Garassino Marina C, Gadgeel Shirish,Speranza Giovanna et al. Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study.[J] .J Clin Oncol, 2023, 41: 1992- 1998.
9. Novello Silvia, Kowalski Dariusz M, Luft Alexander, et al. Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study.[J] .J Clin Oncol, 2023, 41: 1999-2006.
10. Caicun Zhou, et al. First-line camrelizumab (Camre) plus carboplatin (Carbo) and pemetrexed (Pem) for advanced non-squamous NSCLC: 5-yr outcomes of CameL phase III study. 2024 ELCC 61P.
11. Caicun Zhou, et al. Camrelizumab plus chemotherapy (Cam-chemo) as first-line (1L) therapy for advanced squamous non-small cell lung cancer (sqNSCLC): 5y update from the phase III CameL-sq trial. 2025 ELCC 12P.
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
#非小细胞肺癌#
14